Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

NCT01848925 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Sickle Cell Disease

Interventions

BIOLOGICAL: SANGUINATE™
DRUG: Hydroxyurea

Sponsor

Prolong Pharmaceuticals